OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
October 15, 2021
Navigating a complex global regulatory landscape involves upfront research into the expectations of the different regulatory bodies, thorough documentation of every step of the API manufacturing process, and good communication.
Between dosage form versatility, product stability, lack of storage restrictions or need to refrigerate, and an easier means of purification, small-molecule APIs present an appealing market niche.
October 03, 2021
Drug makers are going beyond continuous improvement and green chemistry to increase the sustainability of small-molecule manufacturing.
September 21, 2021
AstraZeneca will establish an API manufacturing facility near Dublin, Ireland.
August 19, 2021
Curia plans to expand the site’s commercial capabilities with this move.
August 17, 2021
Biotage’s new facility in Cardiff, UK, will produce lipids using large-scale flash purification.
August 13, 2021
Almac Sciences has signed a manufacturing agreement with Pila Pharma for the production of the API XEN-D0501.
July 16, 2021
The new lab near Continuus Pharmaceutical’s current facilities in Massachusetts will expand the company’s process development capabilities to high-potency drugs.
July 12, 2021
UltraBurst has a high disintegration speed, which is for all market segments, from prescriptions to nutraceuticals.
April 26, 2021
Lonza’s new complex will occupy 2000 m2 of the facility with six levels of manufacturing space and will provide room for future small-molecule technologies expansion.